Leadership

Home / Leadership
The WinSanTor Team consists of opinion leaders with unique insights into the development of neuropathy treatments and experts with a strong track record in the biopharmaceutical industry:

Stanley Kim, JD, Co-Founder and acting CEO: A seasoned entrepreneur who has founded and launched several companies in diverse industries, including pharmaceutical/ biotechnology, medical device and software.  His first two companies he co-founded have been been acquired by Qualcomm and Apple.

Nigel Calcutt, Ph.D. (Co-Founder): Nigel is the Professor of Pathology at the University of California, San Diego, has studied diabetic neuropathy and potential therapeutics since his undergraduate studies with Professor David Tomlinson in 1983. Has been involved in the preclinical and clinical development programs for various aldose reductase inhibitors and assorted nerve growth promoting factors and has also served as contractor, consultant and advisory board member for many companies engaged in developing therapies for diabetic neuropathy. Serves as the lead preclinical contractor to the NIH NIDDK-RAID program, where his laboratory assists applicants wishing to enroll their therapy into the NIH RAID drug development program with their preclinical efficacy studies.

Paul Fernyhough, Ph.D. (Co-Founder): Paul is the Professor and Acting Head of the Department of Pharmacology and Therapeutics at the University of Manitoba, has worked for approximately 20 years in the diabetic neuropathy field, studying the etiology of the disease using in vitro and in vivo approaches. Invented the in vitro drug screen assay utilizing primary sensory neurons that identified the drugs currently under investigation.

Lakshmi P. Kotra, B.Pharm.(Hons)Ph.D. (Co-Founder): Lakshmi is the Director at the Center for Molecular Design and Preformulations at University Health Network and Associate Professor of Medicinal Chemistry at the University of Toronto. Obtained Ph.D. from University of Georgia and PDF training at Wayne State University. Lakshmi authored/co-authored over 100 publications, 20 patents/patent applications and delivered 99 invited talks. Contributed to an array of drug discovery and drug delivery projects including anti-HIV drugs, antibacterials, small molecule mimetics to protein ligands, protein-drug conjugates (PDCs), antimalarials, drugs targeting neurodegeneration and thrombocytopenia. Serves as a board member and as a consultant to a number of biotech companies.